A phase III clinical trial of the new-generation gonadotropin-releasing hormone agonist elagolix met the primary endpoint of reducing abnormal bleeding in women with uterine fibroids, said drugmaker AbbVie.
The American Society of Clinical Oncology and the National Comprehensive Cancer Network recently published clinical guidance for management of side effects associated with immune checkpoint inhibitors.
Surgeons in India removed what is believed to be the largest-ever brain tumor, weighing almost 4 lb. (BBC)
New insights into the hormonal mechanisms that drive male breast cancer. (Netherlands Cancer Institute)